<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Times" color="#000000"/>
	<fontspec id="font1" size="10" family="Times,Italic" color="#000000"/>
	<fontspec id="font2" size="7" family="Times,Italic" color="#000000"/>
	<fontspec id="font3" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font4" size="6" family="Times,Italic" color="#000000"/>
	<fontspec id="font5" size="12" family="Helvetica,Bold" color="#ffffff"/>
	<fontspec id="font6" size="14" family="Times,Bold" color="#ffffff"/>
	<fontspec id="font7" size="10" family="Times,Bold" color="#000000"/>
	<fontspec id="font8" size="10" family="Times" color="#000000"/>
	<fontspec id="font9" size="7" family="Times" color="#000000"/>
	<fontspec id="font10" size="11" family="Helvetica,Bold" color="#000000"/>
	<fontspec id="font11" size="32" family="Times" color="#000000"/>
	<fontspec id="font12" size="18" family="Times,Italic" color="#000000"/>
	<fontspec id="font13" size="13" family="Times,Italic" color="#000000"/>
<text top="42" left="197" width="217" height="8" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">ADVANCING CANCER SYMPTOM CONTROL TRIALS</text>
<text top="765" left="226" width="161" height="9" font="font1" id="p1_t2" reading_order_no="90" segment_no="16" tag_type="text">C URRENT O NCOLOGY — V OLUME 14, N UMBER 3<i>C</i></text>
<text top="755" left="61" width="13" height="11" font="font5" id="p1_t3" reading_order_no="89" segment_no="13" tag_type="text">86<i>URRENT</i></text>
<text top="47" left="217" width="327" height="13" font="font6" id="p1_t4" reading_order_no="1" segment_no="0" tag_type="title">UPDATES AND DEVELOPMENTS IN ONCOLOGY<i> O</i></text>
<text top="666" left="55" width="239" height="9" font="font1" id="p1_t5" reading_order_no="83" segment_no="15" tag_type="text">Richard J. Ablin, PhD , Research Professor of Immuno-<i>NCOLOGY</i></text>
<text top="678" left="55" width="239" height="9" font="font1" id="p1_t6" reading_order_no="84" segment_no="15" tag_type="text">biology, University of Arizona College of Medicine and<i>—</i></text>
<text top="689" left="55" width="239" height="9" font="font1" id="p1_t7" reading_order_no="85" segment_no="15" tag_type="text">the Arizona Cancer Center, Tucson, Arizona, U.S.A., and<i>V</i></text>
<text top="699" left="55" width="239" height="9" font="font1" id="p1_t8" reading_order_no="86" segment_no="15" tag_type="text">Phil Gold, PhD MD , Professor of Medicine, Physiology,<i>OLUME</i></text>
<text top="711" left="55" width="239" height="9" font="font1" id="p1_t9" reading_order_no="87" segment_no="15" tag_type="text">and Oncology, McGill University, Montreal, Quebec,<i> 14, N</i></text>
<text top="722" left="55" width="110" height="9" font="font1" id="p1_t10" reading_order_no="88" segment_no="15" tag_type="text">Canada, Section Editors.<i>UMBER</i></text>
<text top="249" left="73" width="149" height="9" font="font7" id="p1_t11" reading_order_no="6" segment_no="3" tag_type="title">Canadian Institutes of Health:<i> 3</i></text>
<text top="260" left="73" width="183" height="9" font="font7" id="p1_t12" reading_order_no="7" segment_no="5" tag_type="title">Research definition of palliative care:<b>86</b></text>
<text top="270" left="73" width="203" height="9" font="font8" id="p1_t13" reading_order_no="8" segment_no="6" tag_type="text">Palliative care aims to improve the life of pa-<b>UPDATES AND DEVELOPMENTS IN ONCOLOGY</b></text>
<text top="282" left="73" width="203" height="9" font="font8" id="p1_t14" reading_order_no="9" segment_no="6" tag_type="text">tients and families through the early identifi-<i>Richard J. Ablin, </i></text>
<text top="293" left="73" width="203" height="9" font="font8" id="p1_t15" reading_order_no="10" segment_no="6" tag_type="text">cation and impeccable management of<i>PhD</i></text>
<text top="303" left="73" width="203" height="9" font="font8" id="p1_t16" reading_order_no="11" segment_no="6" tag_type="text">suffering associated with advanced illness and<i>, Research Professor of Immuno-</i></text>
<text top="315" left="73" width="203" height="9" font="font8" id="p1_t17" reading_order_no="12" segment_no="6" tag_type="text">emphasis on the positive aspects of life in-<i>biology, University of Arizona College of Medicine and</i></text>
<text top="326" left="73" width="203" height="9" font="font8" id="p1_t18" reading_order_no="13" segment_no="6" tag_type="text">clusive of physical, psychosocial and spiri-<i>the Arizona Cancer Center, Tucson, Arizona, U.S.A., and</i></text>
<text top="336" left="73" width="203" height="9" font="font8" id="p1_t19" reading_order_no="14" segment_no="6" tag_type="text">tual sources. Palliative care is an exercise in<i>Phil Gold, </i></text>
<text top="348" left="73" width="203" height="9" font="font8" id="p1_t20" reading_order_no="15" segment_no="6" tag_type="text">prevention—prevention of suffering through<i>PhD</i></text>
<text top="359" left="73" width="203" height="9" font="font8" id="p1_t21" reading_order_no="16" segment_no="6" tag_type="text">prioritizing the diagnosis and skillful care of<i>MD</i></text>
<text top="369" left="73" width="203" height="9" font="font8" id="p1_t22" reading_order_no="17" segment_no="6" tag_type="text">sources of distress throughout the course of<i>, Professor of Medicine, Physiology,</i></text>
<text top="381" left="73" width="203" height="9" font="font8" id="p1_t23" reading_order_no="18" segment_no="6" tag_type="text">illness and for the family into the bereave-<i>and Oncology, McGill University, Montreal, Quebec,</i></text>
<text top="392" left="73" width="203" height="9" font="font8" id="p1_t24" reading_order_no="19" segment_no="6" tag_type="text">ment period. It is not simply an end of life<i>Canada, Section Editors.</i></text>
<text top="402" left="73" width="203" height="9" font="font8" id="p1_t25" reading_order_no="20" segment_no="6" tag_type="text">concept separate from other aspects of re-<b>Canadian Institutes of Health:</b></text>
<text top="414" left="73" width="203" height="9" font="font8" id="p1_t26" reading_order_no="21" segment_no="6" tag_type="text">search and control. Palliative care research<b>Research definition of palliative care:</b></text>
<text top="425" left="73" width="203" height="9" font="font8" id="p1_t27" reading_order_no="22" segment_no="6" tag_type="text">focuses on fundamental symptom mecha-</text>
<text top="435" left="73" width="203" height="9" font="font8" id="p1_t28" reading_order_no="23" segment_no="6" tag_type="text">nisms as well as the experience of the patient</text>
<text top="447" left="73" width="69" height="9" font="font8" id="p1_t29" reading_order_no="24" segment_no="6" tag_type="text">and the family.</text>
<text top="458" left="90" width="186" height="9" font="font8" id="p1_t30" reading_order_no="25" segment_no="9" tag_type="text">—Adapted, with thanks, from the World</text>
<text top="468" left="183" width="93" height="9" font="font8" id="p1_t31" reading_order_no="26" segment_no="9" tag_type="text">Health Organization</text>
<text top="491" left="55" width="239" height="9" font="font8" id="p1_t32" reading_order_no="27" segment_no="10" tag_type="text">The preceding palliative care definition, endorsed by</text>
<text top="501" left="55" width="239" height="9" font="font8" id="p1_t33" reading_order_no="28" segment_no="10" tag_type="text">the Canadian Institutes of Health Research (CIHR)</text>
<text top="513" left="55" width="239" height="9" font="font8" id="p1_t34" reading_order_no="29" segment_no="10" tag_type="text">Institute of Cancer Research, emphasizes early iden-</text>
<text top="524" left="55" width="239" height="9" font="font8" id="p1_t35" reading_order_no="30" segment_no="10" tag_type="text">tification of sources of suffering in cancer patients</text>
<text top="534" left="55" width="239" height="9" font="font8" id="p1_t36" reading_order_no="31" segment_no="10" tag_type="text">and, by inference, the importance of clinical trials on</text>
<text top="546" left="55" width="239" height="9" font="font8" id="p1_t37" reading_order_no="32" segment_no="10" tag_type="text">symptom-control therapies introduced early in a</text>
<text top="557" left="55" width="239" height="9" font="font8" id="p1_t38" reading_order_no="33" segment_no="10" tag_type="text">patient’s course of illness. This noble objective is fully</text>
<text top="567" left="55" width="239" height="9" font="font8" id="p1_t39" reading_order_no="34" segment_no="10" tag_type="text">in keeping with the reports of an influential panel</text>
<text top="579" left="55" width="239" height="9" font="font8" id="p1_t40" reading_order_no="35" segment_no="10" tag_type="text">which recommends that patients and families have</text>
<text top="590" left="55" width="239" height="9" font="font8" id="p1_t41" reading_order_no="36" segment_no="10" tag_type="text">access to the full range of care measures at disease</text>
<text top="599" left="55" width="34" height="10" font="font8" id="p1_t42" reading_order_no="37" segment_no="10" tag_type="text">1 onset .</text>
<text top="612" left="73" width="221" height="9" font="font8" id="p1_t43" reading_order_no="38" segment_no="14" tag_type="text">Today, few would disagree with the concept that</text>
<text top="623" left="55" width="239" height="9" font="font8" id="p1_t44" reading_order_no="39" segment_no="14" tag_type="text">therapy for symptom and psychosocial problems</text>
<text top="633" left="55" width="239" height="9" font="font8" id="p1_t45" reading_order_no="40" segment_no="14" tag_type="text">should be integrated with traditional measures of</text>
<text top="249" left="318" width="239" height="9" font="font8" id="p1_t46" reading_order_no="41" segment_no="4" tag_type="text">curing or controlling cancer (surgery, radiotherapy,</text>
<text top="260" left="318" width="239" height="9" font="font8" id="p1_t47" reading_order_no="42" segment_no="4" tag_type="text">chemotherapy). However, model programs blending</text>
<text top="270" left="318" width="239" height="9" font="font8" id="p1_t48" reading_order_no="43" segment_no="4" tag_type="text">these elements of care from diagnosis are still not</text>
<text top="282" left="318" width="43" height="9" font="font8" id="p1_t49" reading_order_no="44" segment_no="4" tag_type="text">common.</text>
<text top="293" left="336" width="221" height="9" font="font8" id="p1_t50" reading_order_no="45" segment_no="7" tag_type="text">Cancer centres may be making progress in mov-</text>
<text top="303" left="318" width="239" height="9" font="font8" id="p1_t51" reading_order_no="46" segment_no="7" tag_type="text">ing from rhetoric to reality, but slowly in the clinical</text>
<text top="315" left="318" width="239" height="9" font="font8" id="p1_t52" reading_order_no="47" segment_no="7" tag_type="text">research sphere. For example, anorexia–cachexia is</text>
<text top="326" left="318" width="239" height="9" font="font8" id="p1_t53" reading_order_no="48" segment_no="7" tag_type="text">often encountered early in the course of the illness,</text>
<text top="336" left="318" width="239" height="9" font="font8" id="p1_t54" reading_order_no="49" segment_no="7" tag_type="text">but research on the problem is modest. In 2005, 15 of</text>
<text top="348" left="318" width="239" height="9" font="font8" id="p1_t55" reading_order_no="50" segment_no="7" tag_type="text">4917 abstracts published by the American Society of</text>
<text top="359" left="318" width="239" height="9" font="font8" id="p1_t56" reading_order_no="51" segment_no="7" tag_type="text">Clinical Oncology were concerned with cancer nu-</text>
<text top="369" left="318" width="239" height="9" font="font8" id="p1_t57" reading_order_no="52" segment_no="7" tag_type="text">trition, including cancer cachexia. Only a few of these</text>
<text top="381" left="318" width="239" height="9" font="font8" id="p1_t58" reading_order_no="53" segment_no="7" tag_type="text">were clinical trials, with small patient enrolment. No</text>
<text top="392" left="318" width="239" height="9" font="font8" id="p1_t59" reading_order_no="54" segment_no="7" tag_type="text">progress was seen in 2006, with its 10 nutrition pre-</text>
<text top="402" left="318" width="239" height="9" font="font8" id="p1_t60" reading_order_no="55" segment_no="7" tag_type="text">sentations. Research presentations on the problems</text>
<text top="414" left="318" width="239" height="9" font="font8" id="p1_t61" reading_order_no="56" segment_no="7" tag_type="text">of chronic symptoms—aside from those on pain (a</text>
<text top="425" left="318" width="239" height="9" font="font8" id="p1_t62" reading_order_no="57" segment_no="7" tag_type="text">dramatic, acute source of suffering demanding im-</text>
<text top="435" left="318" width="166" height="9" font="font8" id="p1_t63" reading_order_no="58" segment_no="7" tag_type="text">mediate attention)—continue to lag.</text>
<text top="447" left="336" width="221" height="9" font="font8" id="p1_t64" reading_order_no="59" segment_no="8" tag_type="text">Because of the common presence of cancer anor-</text>
<text top="458" left="318" width="239" height="9" font="font8" id="p1_t65" reading_order_no="60" segment_no="8" tag_type="text">exia–cachexia as a source of patient–family distress,</text>
<text top="468" left="318" width="239" height="9" font="font8" id="p1_t66" reading_order_no="61" segment_no="8" tag_type="text">and because of its devastating effects (loss of func-</text>
<text top="480" left="318" width="239" height="9" font="font8" id="p1_t67" reading_order_no="62" segment_no="8" tag_type="text">tion, and consequent dependency and poorer progno-</text>
<text top="491" left="318" width="239" height="9" font="font8" id="p1_t68" reading_order_no="63" segment_no="8" tag_type="text">sis), I will use that symptom as a theme to illustrate</text>
<text top="501" left="318" width="239" height="9" font="font8" id="p1_t69" reading_order_no="64" segment_no="8" tag_type="text">problems in conducting clinical studies that need to</text>
<text top="513" left="318" width="220" height="9" font="font8" id="p1_t70" reading_order_no="65" segment_no="8" tag_type="text">enlist patients early in the course of their illness.</text>
<text top="534" left="318" width="235" height="10" font="font10" id="p1_t71" reading_order_no="66" segment_no="11" tag_type="title">DIFFICULTIES WITH TRIAL  ENROLMENT  AND</text>
<text top="545" left="318" width="54" height="10" font="font10" id="p1_t72" reading_order_no="67" segment_no="11" tag_type="title">DROPOUT</text>
<text top="567" left="318" width="239" height="9" font="font8" id="p1_t73" reading_order_no="68" segment_no="12" tag_type="text">I recently served as the Canadian Principal Investi-</text>
<text top="579" left="318" width="239" height="9" font="font8" id="p1_t74" reading_order_no="69" segment_no="12" tag_type="text">gator ( PI ) for an international anorexia trial. Cana-</text>
<text top="590" left="318" width="239" height="9" font="font8" id="p1_t75" reading_order_no="70" segment_no="12" tag_type="text">dian patients represented approximately 25% of the</text>
<text top="599" left="318" width="239" height="10" font="font8" id="p1_t76" reading_order_no="71" segment_no="12" tag_type="text">patients enrolled in that study 2 , but most came from</text>
<text top="612" left="318" width="239" height="9" font="font8" id="p1_t77" reading_order_no="72" segment_no="12" tag_type="text">my home institution, one other academic centre, and</text>
<text top="623" left="318" width="239" height="9" font="font8" id="p1_t78" reading_order_no="73" segment_no="12" tag_type="text">a community cancer centre; enrolment from our larg-</text>
<text top="633" left="318" width="239" height="9" font="font8" id="p1_t79" reading_order_no="74" segment_no="12" tag_type="text">est cancer centres was poor. When the local investi-</text>
<text top="645" left="318" width="239" height="9" font="font8" id="p1_t80" reading_order_no="75" segment_no="12" tag_type="text">gators were asked about their low enrolment, they</text>
<text top="656" left="318" width="239" height="9" font="font8" id="p1_t81" reading_order_no="76" segment_no="12" tag_type="text">replied that they had had difficulty in keeping the</text>
<text top="666" left="318" width="239" height="9" font="font8" id="p1_t82" reading_order_no="77" segment_no="12" tag_type="text">trial “front and centre” with their oncology colleagues.</text>
<text top="678" left="318" width="239" height="9" font="font8" id="p1_t83" reading_order_no="78" segment_no="12" tag_type="text">Failure to recommend patients for the trial until</text>
<text top="689" left="318" width="239" height="9" font="font8" id="p1_t84" reading_order_no="79" segment_no="12" tag_type="text">cachexia was far advanced was also a problem. An-</text>
<text top="699" left="318" width="239" height="9" font="font8" id="p1_t85" reading_order_no="80" segment_no="12" tag_type="text">other major reason expressed for the delay in trial</text>
<text top="711" left="318" width="239" height="9" font="font8" id="p1_t86" reading_order_no="81" segment_no="12" tag_type="text">consideration was competition with conventional</text>
<text top="722" left="318" width="151" height="9" font="font8" id="p1_t87" reading_order_no="82" segment_no="12" tag_type="text">cancer chemoradiotherapy trials.<b>DIFFICULTIES WITH TRIAL  ENROLMENT  AND</b></text>
<text top="81" left="217" width="228" height="29" font="font11" id="p1_t88" reading_order_no="2" segment_no="1" tag_type="title">Cancer symptom<b>DROPOUT</b></text>
<text top="115" left="217" width="311" height="29" font="font11" id="p1_t89" reading_order_no="3" segment_no="1" tag_type="title">control trials: how may</text>
<text top="149" left="217" width="298" height="29" font="font11" id="p1_t90" reading_order_no="4" segment_no="1" tag_type="title">we advance this field?</text>
<text top="199" left="217" width="169" height="16" font="font12" id="p1_t91" reading_order_no="5" segment_no="2" tag_type="text">N. MacDonald CM MD</text>
</page>
</pdf2xml>
